|1.||Scanlan, Thomas S: 6 articles (04/2007 - 03/2004)|
|2.||Webb, Paul: 5 articles (07/2013 - 07/2005)|
|3.||Baxter, John D: 4 articles (12/2012 - 04/2004)|
|4.||Olofsson, Sigvard: 2 articles (02/2015 - 04/2013)|
|5.||Larson, Göran: 2 articles (02/2015 - 04/2013)|
|6.||Nilsson, Jonas: 2 articles (02/2015 - 04/2013)|
|7.||Nordén, Rickard: 2 articles (02/2015 - 04/2013)|
|8.||Halim, Adnan: 2 articles (02/2015 - 04/2013)|
|9.||Nyström, Kristina: 2 articles (02/2015 - 04/2013)|
|10.||Baxter, John: 2 articles (07/2013 - 07/2005)|
|2.||Body Weight (Weight, Body)
07/01/2006 - "Rats treated with GC-1 (50 or 100 mug/100 g body weight) were killed at different time points. "
04/01/2004 - "T(3) and GC-1 caused a significant (approximately 4%) reduction in body weight in these animals. "
04/01/2007 - "In the current study, we compared the effects of a 6-week treatment with triiodothyronine (T3; daily injections of 3 or 6 microg/100 g body weight) or GC-1 (equimolar doses) on different metabolic parameters in adult female rats. "
09/01/2000 - "T3, but not GC-1, normalized heart and body weights and messenger RNAs of myosin heavy chain alpha and beta and the sarcoplasmic reticulum adenosine triphosphatase (Serca2). "
04/01/2004 - "For these studies, the TRbeta selective agonist, GC-1, was used to assess selectivity for lipid-lowering and metabolic rate changes relative to tachycardia. "
04/01/2004 - "GC-1 showed approximately 10-fold selectivity for increasing metabolic rate (ED(5) = 477 nmol/kg x d) relative to tachycardia compared with T(3), which showed no selectivity. "
04/01/2004 - "Studies in cholesterol-fed rats (7 d treatment) showed that GC-1 reduced cholesterol (ED(50) = 190 nmol/kg x d) approximately 30 times more potently than it induced tachycardia (ED(15) = 5451 nmol/kg x d). "
04/01/2004 - "In cynomolgus monkeys treated for 7 d, significant cholesterol-lowering and lipoprotein (a) reduction was noted for both T(3) and GC-1, whereas no tachycardia was observed for GC-1, unlike T(3). "
11/16/2009 - "Immunizing mice with gD-1 and gC-1 provided better protection than gD-1 alone in preventing zosteriform disease and infection of dorsal root ganglia. "
02/20/2015 - "Using HSV-1-infected diploid human fibroblasts, an authentic target for HSV-1 infection, and a protein immunoaffinity procedure, we enriched fully glycosylated gC-1 and a series of its biosynthetic intermediates. "
04/01/2013 - "Involvement of viral glycoprotein gC-1 in expression of the selectin ligand sialyl-Lewis X induced after infection with herpes simplex virus type 1."
09/07/2005 - "Therefore, gC-1 immunization in humans may also induce blocking antibodies that modify disease, despite the rather limited ability of infection to produce these antibodies."
09/07/2005 - "Mice infected with HSV-1 produced antibodies that partially blocked C3b binding at lower IgG concentrations than human IgG. Importantly, gC-1 immunization in mice produced higher titers of gC-1 antibodies than infection. "
04/01/2007 - "These findings highlight the potential use of GC-1 for the treatment of obesity and the metabolic syndrome."
09/01/2000 - "These data indicate that GC-1 could represent a prototype for new drugs for the treatment of high lipid levels or obesity."
01/01/2008 - "These results shed light into the beta-selectivity of GC-1 and may assist the development of new compounds with potential as drug candidates to the treatment of hypercholesterolemia and obesity."
07/01/2006 - "Because of the selective hyperthyroidism generated by one of these agonists, GC-1, this compound has the potential to be developed as a new therapeutic agent for the treatment of a variety of metabolic disturbances, including lipid disorders and obesity; thus, it becomes important to determine whether GC-1 has other unknown effects on potential target organs. "
|3.||Thyroid Hormone Receptors beta (TR beta)
|8.||TNF Receptor-Associated Factor 2 (TRAF2)
|9.||Small Interfering RNA (siRNA)